Health Coalition’s Cost-Cutting Pledge Needs Five-Year Target - Orszag
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharma’s eventual role in cost reduction remains unclear; FOBs unlikely to yield savings short-term.
You may also be interested in...
Obama Medicaid Rebate Provisions Make Way Into Finance Cmte. Options
The Senate Finance Committee is looking to the pharmaceutical industry to contribute to paying for health care reform in the form of adjustments to Medicaid rebates and the introduction of means testing in Medicare Part D
Bending The Cost Curve: Obama Presses For Specifics On Coalition Pledge
The White House is expecting a private sector healthcare coalition - including the pharmaceutical industry - to produce details in early June on a pledge to help reduce the annual health care spending growth rate by 1.5 percentage points over the next 10 years
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.